VolitionRx Announces Pricing of $4.6 Million Public Offering

VolitionRx Limited (NYSE AMERICAN: VNRX), a multi-national epigenetics company, has announced the pricing of its public offering of 2,960,000 shares of common stock, along with warrants to purchase an additional 1,480,000 shares. The offering, which is expected to close on June 9, 2026, aims to raise approximately $4.6 million in gross proceeds, with potential additional proceeds of $2.3 million from the exercise of the warrants. The shares and accompanying half warrants are being offered at a combined price of $1.55 per share.

VolitionRx is focused on advancing the science of epigenetics, particularly in the development of blood tests for early disease detection and monitoring. The company aims to improve patient outcomes through its innovative diagnostic tools, which target various diseases, including certain cancers and conditions associated with NETosis, such as sepsis. With research and development activities based in Belgium, VolitionRx also maintains operations in the U.S. and London, positioning itself as a key player in the growing diagnostics sector.

The strategic rationale behind this public offering is likely to enhance the company’s financial flexibility and support its ongoing research and development efforts. The funds raised will allow VolitionRx to further its mission of providing cost-effective and easy-to-use blood tests, which are essential in the early detection of life-altering diseases. The participation of both new and existing investors in this offering indicates a level of confidence in Volition's growth potential and market position.

The broader diagnostics market is experiencing significant growth, driven by advancements in technology and an increasing emphasis on early disease detection. As healthcare systems worldwide continue to prioritize preventive care, companies like VolitionRx that focus on innovative diagnostic solutions are well-positioned to capitalize on these trends. The successful completion of this public offering could provide VolitionRx with the necessary capital to expand its product offerings and enhance its competitive advantage in the diagnostics space.

Overall, the public offering by VolitionRx Limited reflects a strategic move to bolster its financial resources in a rapidly evolving market. As the company continues to develop its epigenetic technologies, it may play a pivotal role in transforming the landscape of disease detection and management, thereby contributing to improved healthcare outcomes on a global scale.